Welcome to our dedicated page for Inotiv SEC filings (Ticker: NOTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inotiv, Inc. (NASDAQ: NOTV) SEC filings page on Stock Titan provides centralized access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-assisted summaries to help interpret key points. Inotiv is a contract research organization offering nonclinical and analytical drug discovery and development services and research models and related products and services, and its filings offer detailed insight into how this business operates and evolves.
Through periodic and current reports, investors can review how Inotiv reports performance in its Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments, including revenue drivers such as safety assessment services, general toxicology, biotherapeutic analysis, discovery and translational sciences services, and non-human primate product and service revenues. Annual and quarterly reports (such as Forms 10-K and 10-Q, when available) typically include segment discussions, risk factors, liquidity and capital resources, and descriptions of non-GAAP measures like Adjusted EBITDA that the company uses to evaluate its operations.
Current reports on Form 8-K, several of which are reflected in the recent data, highlight material events such as preliminary financial results, corrections to earnings releases, cybersecurity incidents, and legal and regulatory developments. Examples include disclosures about a cybersecurity incident affecting certain systems and data, proposed settlements of securities class action and derivative litigation, updates on investigations related to non-human primate importations, and engagement of financial advisors to explore potential debt refinancing alternatives.
Stock Titan’s interface is designed to surface these filings in real time as they are posted to EDGAR, while AI-generated explanations can help clarify complex sections, such as litigation descriptions, settlement terms, governance commitments, and capital structure updates. Users can also review insider and executive-related filings, such as Forms 3, 4, and 5 when available, to understand equity transactions by officers and directors.
By using the NOTV SEC filings page, investors and researchers can quickly locate Inotiv’s official regulatory communications and rely on AI tools to interpret how reported financial results, risk disclosures, legal matters, and strategic initiatives relate to the company’s nonclinical and research model-focused business.
Inotiv Inc. insider filing outlines planned stock sales under Rule 144. The notice covers up to 20,000 shares of common stock to be sold through Raymond James & Associates on or about February 17, 2026 on the NASDAQ, with an aggregate market value of $5,800 and total shares outstanding of 34,390,000.
The seller previously acquired 55,000 common shares on February 16, 2026 via an RSU grant from the issuer, with cash payment dated February 17, 2026. During the prior three months, the filer, Robert Leasure, sold 113,297 common shares on February 6, 2026 for gross proceeds of $56,216.
Inotiv, Inc. reported quarterly revenue of
Total assets were
Inotiv, Inc. reported first quarter fiscal 2026 results showing nearly flat revenue but continued losses. Revenue for the three months ended December 31, 2025 was $120.9 million, up 0.8% from $119.9 million a year earlier. Discovery & Safety Assessment revenue grew 12.0% to $48.0 million, while Research Models & Services revenue declined 5.4% to $72.9 million, mainly from lower non-human primate volumes.
Operating loss increased to $16.3 million from $15.5 million, and consolidated net loss widened slightly to $28.4 million. Adjusted EBITDA was $1.8 million, or 1.5% of revenue, compared with $2.6 million, or 2.2%, in the prior-year quarter. Cash and cash equivalents declined to $12.7 million at December 31, 2025 from $21.7 million at September 30, 2025, while total debt was $405.8 million. For the DSA services business, the book-to-bill ratio was 1.16x and backlog rose to $145.4 million, indicating growing contracted work despite current losses.
Inotiv President and CEO Robert Leasure Jr. had 113,297 shares of common stock automatically sold on February 2, 2026 at a weighted average price of $0.5034 per share to satisfy tax withholding obligations on vested restricted stock units.
Following this sell-to-cover transaction, he directly beneficially owned 1,273,025 common shares. An additional 105,000 shares are held by an entity for which he is the majority security holder, and he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
A holder of NOTV common stock has filed a notice of proposed sale under Rule 144. The filer plans to sell 120,000 shares through Raymond James & Associates on or about 02/02/2026 on the NASDAQ market, with an aggregate market value of $59,088.00. The issuer had 34,400,000 shares outstanding. The securities to be sold are part of a 300,000-share RSU grant of common stock acquired on 02/01/2026, with cash payment dated 02/02/2026.
Inotiv, Inc. files an amended annual report to add detailed Part III information on directors, executive compensation, ownership and auditor fees, without revising previously reported financial results. The filing describes a largely independent board with a separate, independent chair and CEO roles.
For fiscal 2025, executives received base salary increases and significant stock-based incentives, but no annual cash bonuses were paid despite approved bonus targets. CEO total compensation was $2,941,549, and the CEO pay ratio was 50:1 versus a median employee at $58,998. Directors and executives as a group beneficially owned about 10.7% of common shares.
Inotiv, Inc. reported that a federal court has issued a preliminary approval order for a proposed settlement of consolidated stockholder derivative actions in federal and Indiana state court. Under the proposed settlement, the company will implement certain corporate governance measures and receive a $2,490,000 payment for its benefit funded entirely by available insurance, which it plans to use as part of a payment to members of a putative class in a related securities class action settlement.
Plaintiffs in the derivative cases will also seek court-approved attorneys’ fees of up to $2,250,000, which the company expects to be fully paid by insurance. A final approval hearing is scheduled for March 18, 2026, and the stipulation states there is no admission of liability by the defendants or the company.
Inotiv, Inc.$0.5956 per share and were awarded as a non-qualified stock option grant. According to the filing, the options vest over three years on a 40% / 30% / 30% schedule beginning on the first anniversary of the
Inotiv, Inc. reported that on December 31, 2025 it received a written notice from Nasdaq that its common stock is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share for 30 consecutive business days. The notice does not immediately affect the listing or trading of the common shares on Nasdaq.
Inotiv has 180 calendar days, until June 29, 2026, to regain compliance by having its stock close at or above $1.00 per share for at least 10 consecutive business days, subject to Nasdaq’s discretion to require a longer period. If it fails to do so, the company may be eligible for an additional 180-day grace period. Inotiv plans to monitor its share price and evaluate options, but there is no assurance it will regain or maintain compliance with Nasdaq listing requirements.
Inotiv, Inc. (NOTV) announced that it has issued a press release with select preliminary unaudited financial results for its fourth quarter and fiscal year ended September 30, 2025. These early figures are being shared ahead of final audited results to give the market an initial view of the company’s recent performance.
The company also disclosed that President and CEO Robert Leasure, Jr. will present at the Jefferies Global Healthcare Conference on November 18, 2025 at 6:00 a.m. Eastern time. A live webcast and replay of this presentation will be available through the Investors section of Inotiv’s website. The press release containing the preliminary results is furnished as Exhibit 99.1.